News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CeMines Inc. Appoints Dr. K.C. Nicolaou As Co-Chairman - Scientific Advisory Board



10/19/2005 5:12:20 PM

GOLDEN, Colo., Jan. 17 /PRNewswire/ -- CeMines(TM) Inc., a life sciences company specializing in molecular research and development of minimally invasive clinical diagnostics and targeted therapeutics for cancer, today announced that K.C. Nicolaou, Ph.D., one of the world's foremost authorities on the total synthesis of naturally occurring molecules and inventor of important biologically active molecules, has been appointed Co-Chairman of the Company's Scientific Advisory Board, effective immediately.

Dr. Nicolaou, Chairman of the Department of Chemistry and Darlene Shiley Professor at The Scripps Research Institute, was elected in 1996 to membership in the prestigious National Academy of Sciences in recognition of his outstanding scientific achievements.

"K.C. possesses a remarkable ability to choose drug targets that not only provide the opportunity for novel chemistry, but also represent the cutting- edge of cell biology and molecular medicines," said Roger Attick, CEO of CeMines. "Since the late-1980s, K.C. and his team have been responsible for astonishing synthetic firsts. I am ecstatic he chose to join the CeMines team. Realizing that K.C. reached his decision upon evaluation of our diagnostic protocols, and after taking a peek at our early therapeutics development and drug delivery initiatives, two things are clear to me: 1) As first mentioned in the MD Buyline Research Report, 'CeMines Molecular FingerPrinting will Revolutionize Cancer Testing', and, 2) K.C. shares similar DNA to that of the CeMines Team. It is not only validation, but an incredible compliment," added Mr. Attick.

Dr. Nicolaou and his team are widely recognized for their work in developing compounds from nature into promising pharmaceuticals. For example, his team synthesized calicheamicin, a bacterial-derived substance that became the targeted anticancer agent Mytotarg(TM); Taxol(TM) (the widely used anticancer drug); and, vancomycin (the 'antibiotic of last resort'). Recently, his group designed and synthesized a series of epothilone analogs, one of which is currently in clinical trials as a potential new anticancer drug.

"CeMines is poised to make important and significant contributions to the diagnosis of serious diseases such as cancer, and move beyond to searching for cures. The Company's timely and ambitious technologies are both challenging and exciting, and I look forward to the opportunity of contributing to its success," said Dr. K.C. Nicolaou.

Dr. Toomas Neuman, CeMines' Chief Scientific Officer and Chairman of the Scientific Advisory Board, said, "KC will add tremendous incremental value as we accelerate our therapeutic research initiatives. We will also evaluate options, relative to CeMines' future development of Theranostics technology."

Dr. Nicolaou's awards and honors include: the American Chemical Society (ACS) Award for Creative Work in Synthetic Organic Chemistry, 1993; the Paul Janssen Prize for Creativity in Organic Synthesis, 1994; the ACS (New York Section) William H. Nichols Medal, 1996; the ACS Ernest Guenther Award in the Chemistry of Natural Products, 1996; the Chemical Pioneer of the American Institute of Chemists Award, 1996; the ACS Linus Pauling Medal, 1996; the ACS (Northeastern Section) Gustavus John Esselen Award for Chemistry in the Public Interest, 1998; the Aspirin Prize for Solidarity Through Chemistry, Spain, 1999; the Ernst Schering Prize, Ernst Schering Research Foundation, 2001; the Nagoya Medal of Organic Chemistry, Nagoya University, Nagoya, Japan, 2001; the Tetrahedron Prize for Creativity in Organic Chemistry, 2002; the ACS Nobel Laureate Signature Award for Graduate Education in Chemistry, 2003; the Aristeio Bodossaki Prize, Bodossaki Foundation, Greece, 2004; and the ACS Arthur C. Cope Award, 2005.

CeMines(TM) Inc., a life sciences company specializing in molecular research, is developing minimally invasive clinical diagnostic tests and targeted therapeutics for cancer. CeMines' novel approach to understanding human cellular regulatory mechanisms resulted in the discovery of CeMines Molecular FingerPrinting(TM), a patent-pending bioinformatics process for identification of and profiling cancer cells. CeMines' headquarters is in Golden, Colorado: http://www.cemines.com/.

CeMines Inc.

CONTACT: Ronald Trahan, APR of Ronald Trahan Associates, Inc., +1-781-762-9782, ext. 18


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES